Physician profile
Jonathan D Sher
NPI 1730171422
$1,616.75
in general payments reported to CMS, 2019-2025
10 companies · $93.80 in 2025
The $93.80 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $44.59 · 2021: $321 · 2022: $626 · 2023: $197 · 2024: $139 · 2025: $93.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $426.10 | 2022-2024 | Infuse |
| Heru, INC. | $355.44 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.74 | 2019-2021 | |
| Alcon Vision LLC | $221.24 | 2019-2025 | Total30, Precision7 |
| Coopervision INC. | $213.14 | 2019-2025 | Misight Contact Lens |
| Carl Zeiss Meditec USA, INC. | $32.41 | 2022 | |
| Abb Con-Cise Optical Group LLC | $25.99 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.64 | 2022 | |
| Maculogix, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.